Scott MacDonald

发表

Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial.

M. Schechter, A. Anis, D. Guh, 2016, JAMA psychiatry.

Hydromorphone ComparedWith Diacetylmorphine for Long-termOpioid Dependence A Randomized Clinical Trial

M. Schechter, A. Anis, D. Guh, 2016 .

Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study

E. Oviedo-Joekes, Scott MacDonald, Charles Boissonneault, 2020, Substance Abuse Treatment, Prevention, and Policy.

Physician Communication in Injectable Opioid Agonist Treatment: Collecting Patient Ratings With the Communication Assessment Tool

M. Schechter, D. Guh, D. Marsh, 2020, Journal of addiction medicine.

Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline

B. Le Foll, E. Oviedo-Joekes, N. Fairbairn, 2019, Canadian Medical Association Journal.

The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency

M. Schechter, D. Guh, Kirsten Marchand, 2015, Substance Abuse Treatment, Prevention, and Policy.

Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder.

M. Schechter, A. Anis, D. Guh, 2017, Drug and alcohol dependence.

Cost‐effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial

N. Bansback, M. Schechter, A. Anis, 2018, Addiction.

Men’s and women’s response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder

M. Schechter, A. Anis, D. Guh, 2017, Substance Abuse Treatment, Prevention, and Policy.

Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with injectable opioid agonist treatment patients

D. Marsh, Heather Palis, Kirsten Marchand, 2021 .

Survival Rates of Teeth with Primary Endodontic Treatment after Core/Post and Crown Placement

F. Eichmiller, Scott MacDonald, S. Stover, 2017, Journal of endodontics.

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report

Heather Palis, E. Oviedo-Joekes, Scott MacDonald, 2021, Harm Reduction Journal.

Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods.

M. Schechter, A. Anis, D. Guh, 2019, Journal of substance abuse treatment.

Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling).

N. Bansback, Heather Palis, Kirsten Marchand, 2022, The International journal on drug policy.

Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study

N. Bansback, M. Schechter, Scott Harrison, 2022, Patient preference and adherence.

PPA_A_391532 3405..3413

N. Bansback, M. Schechter, Scott Harrison, 2022 .

Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder

M. Schechter, A. Anis, D. Guh, 2019, Journal of addiction medicine.

Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment

M. Schechter, J. Foreman, Kirsten Marchand, 2020, Substance abuse treatment, prevention, and policy.

Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review

M. Schechter, D. Marsh, Kirsten Marchand, 2019, Substance Abuse Treatment, Prevention, and Policy.

History of Treatment Access and Drug Use among Participants in a Trial Testing Injectable Opioids under Supervision for Long-Term Heroin Injectors

M. Schechter, A. Anis, D. Guh, 2015 .

Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long‐term opioid dependence

M. Schechter, A. Anis, D. Guh, 2018, Drug and alcohol review.

How injectable opioid agonist treatment (iOAT) care could be improved? service providers and stakeholders’ perspectives

N. Bansback, Scott Harrison, E. Oviedo-Joekes, 2023, Drugs: Education, Prevention and Policy.

Longitudinal patterns of cocaine use among patients receiving injectable hydromorphone or diacetylmorphine for the treatment of opioid use disorder: A growth curve modeling approach.

M. Schechter, D. Guh, D. Marsh, 2020, Drug and alcohol dependence.

Patient-centred care for addiction treatment: a scoping review protocol

M. Schechter, D. Marsh, Kirsten Marchand, 2018, BMJ Open.

Predictors of treatment allocation guesses in a randomized controlled trial testing double-blind injectable hydromorphone and diacetylmorphine for severe opioid use disorder

M. Schechter, A. Anis, D. Guh, 2017 .

Changes in daily dose in open-label compared to double-blind: The role of clients’ expectations in injectable opioid agonist treatment

Scott Harrison, E. Oviedo-Joekes, Scott MacDonald, 2023, Addictive behaviors reports.

Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study.

J. Rehm, E. Wood, B. Le Foll, 2023, Journal of substance use and addiction treatment.

The association between nicotine dependence and physical health among people receiving injectable diacetylmorphine or hydromorphone for the treatment of chronic opioid use disorder

M. Schechter, A. Anis, D. Guh, 2018, Addictive behaviors reports.

“As long as that place stays open, I’ll stay alive”: Accessing injectable opioid agonist treatment during dual public health crises

Kaitlyn Jaffe, Scott Harrison, E. Oviedo-Joekes, 2023, Harm Reduction Journal.

Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review

Scott Harrison, E. Oviedo-Joekes, Scott MacDonald, 2023, The International journal on drug policy.

Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study

Scott Harrison, E. Oviedo-Joekes, Scott MacDonald, 2023, BMC Health Services Research.

Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review

Scott Harrison, E. Oviedo-Joekes, Scott MacDonald, 2023, The International journal on drug policy.

A multi-methods and longitudinal study of patients' perceptions in injectable opioid agonist treatment: Implications for advancing patient-centered methodologies in substance use research.

M. Schechter, D. Guh, D. Marsh, 2021, Journal of substance abuse treatment.

Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with patients receiving injectable opioid agonist treatment

M. Schechter, D. Marsh, Heather Palis, 2021, Substance Abuse Treatment, Prevention, and Policy.

Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review

Scott Harrison, E. Oviedo-Joekes, Scott MacDonald, 2023, International Journal of Drug Policy.

Self-managing illicit stimulant use: A qualitative study with patients receiving injectable opioid agonist treatment.

M. Schechter, D. Marsh, Heather Palis, 2020, Drug and alcohol review.

The mobilization of nurse-client therapeutic relationships in injectable opioid agonist treatment: Autonomy, advocacy and action.

J. Foreman, Scott Harrison, E. Oviedo-Joekes, 2023, Journal of substance use and addiction treatment.

The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review

Scott Harrison, E. Oviedo-Joekes, Scott MacDonald, 2023, Substance Abuse Treatment, Prevention, and Policy.

Experiences of serious depression and serious anxiety among clients receiving injectable Opioid Agonist Treatment (iOAT)

E. Oviedo-Joekes, Scott MacDonald, T. Magel, 2023, Journal of Affective Disorders Reports.